Eficacia de bevacizumab tópico en queratopatía lipoidea bilateral primaria
- M. Castro-Rebollo
- M.A. Montes-Mollón
- C. Pérez-Rico
- M.A. Teus
ISSN: 0365-6691
Datum der Publikation: 2011
Ausgabe: 86
Nummer: 11
Seiten: 374-376
Art: Artikel
Andere Publikationen in: Archivos de la Sociedad Española de Oftalmologia
Zusammenfassung
Case report: A 75-year-old man with bilateral idiopathic lipid keratopathy underwent a penetrating keratoplasty in the left eye. One month later, there was deep corneal neovascularisation extending across the bed and the graft-host interface, with a whitish opacity surrounding the vessels. Topical bevacizumab (25mg/mL) was administered 4 times daily for 2 months with partial regression of corneal neovascularization. Discussion: Topical bevacizumab may be useful in preventing a recurrence of lipid deposition after penetrating keratoplasty in patients with bilateral primary lipid keratopathy, although its long-term efficacy needs to be assessed.
Bibliographische Referenzen
- Friedlaender, MH, Cavanagh, HD, Sullivan, WR, Gallagher, MJ, Dickersin, GR. (1977). Bilateral central lipid infiltrates of the cornea. Am J Ophthalmol.. 84. 781
- Manzano, RP, Peyman, GA, Khab, P, Carvounis, PE, Kivilcim, M, Ren, M. (2007). Inhibition of experimental corneal neovascularization by bevacizumab. Br J Ophthalmol.. 91. 804
- Baer, JC, Foster, CS. (1992). Corneal laser photocoagulation for treatment of neovascularization. Ophthalmology. 99. 173
- Oh, JY, Kim, MK, Wee, WR. (2009). Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. Cornea. 28. 1070
- Bock, F, König, Y, Kruse, F, Baier, M, Cursiefen, C. (2008). Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol.. 246. 281